Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that negatively impacted investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2]. - It is alleged that this situation created a significant risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) securities during the period of August 8, 2024 through August 14, 2025, inclusive (“the Class Period”). If you suffered a loss on your Nutex investments, you have until October 21, 2025 to request lead plaintiff appointment. Follow the link below for more information: [CONTACT THE F ...

BANNOCKBURN, Ill., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor conferences: Deutsche Bank Healthcare Summit, being held in New York City, from Wednesday, September 10, 2025 to Thursday, September 11, 2025.Jefferies Healthcare Services Conference, being held in Nashville, on Tuesday, September 30, 2025, including a fi ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nutex Health Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's financial disclosures and practices [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for securities purchased between August 8, 2024, and August 14, 2025, inclusive [1]. - Investors who purchased Nutex securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Allegations Against Nutex Health Inc. - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices, particularly concerning its relationship with HaloMD, a third-party vendor [5]. - Specific claims include that Nutex engaged in a scheme to defraud insurance companies, leading to unsustainable revenue from its arbitration results [5]. - The company is accused of overstating its ability to remediate weaknesses in its internal controls over financial reporting, which affected its accounting for stock-based compensation obligations [5]. - As a result of these alleged misrepresentations, Nutex's business and financial prospects were overstated, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether agilon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 4, 2025 ...

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. and certain officers for alleged violations of federal securities laws during the Class Period from August 8, 2024, to August 14, 2025, seeking damages for affected investors [1][2]. Company Overview - Nutex Health Inc. is a physician-led healthcare services company that operates through three divisions: a hospital division with 24 facilities across 11 states, a population health management division, and real estate [4]. - The company primarily operates as an out-of-network provider, generating over 90% of its net patient service revenue from third-party payors, including commercial insurance and workers' compensation [4]. Legislative Context - The No Surprises Act (NSA), effective January 1, 2022, was enacted to prevent surprise out-of-network billing, requiring private health plans to cover out-of-network claims at in-network cost-sharing rates [6]. - The NSA established an independent dispute resolution (IDR) process for determining out-of-network payment amounts when negotiations fail [7]. Financial Impact - Following the implementation of the NSA, Nutex's average payment from insurers for emergency services declined by approximately 30%, with a 37% reduction for physician services reported in March 2023 [8]. - In 2024, Nutex's total revenue increased by $232.3 million to $479.9 million, with the arbitration process contributing approximately $169.7 million to this revenue increase [9]. Internal Control Issues - Nutex has acknowledged material weaknesses in its internal controls over financial reporting, including ineffective design and implementation of controls related to financial processes [9]. - The company has stated it is in the process of remediating these weaknesses [9]. Allegations and Lawsuits - The lawsuit alleges that Nutex made materially false and misleading statements regarding its business operations and financial prospects, including claims about the sustainability of revenues from its engagement with HaloMD in the IDR process [9]. - Blue Orca Capital's report accused HaloMD of engaging in fraudulent schemes to inflate payments from insurance companies, which could impact Nutex's financial stability [10][11]. Stock Price Reaction - Following the publication of the Blue Orca Report, Nutex's stock price fell by $11.18 per share (10.05%) on July 22, 2025, and further declined by $18.22 per share (16.39%) after the company announced a delay in filing its Form 10-Q on August 15, 2025 [11][13]. Recent Developments - On August 21, 2025, Nutex filed a Current Report with the SEC indicating that certain financial statements would need to be restated due to improper treatment of non-cash obligations [14].

Aveanna Healthcare Holdings Inc. (AVAH) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, AVAH's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common mov ...

24 August 2025 | 3:05PM HKT Topchoice Medical (600763.SS) Earnings Review: 2Q25 revenue/ earnings slightly miss with soft recovery, awaiting policy tailwind into 2H 600763.SS 12m Price Target: Rmb49.00 Price: Rmb46.74 Upside: 4.8% 2Q25 revenue and earnings miss: Revenue of Rmb704mn, +0.2% y/y, 4% below GSe of Rmb733mn, and net profit of Rmb137mn, +0.5% y/y, 2% below GSeRmb140mn. Net margin came in at 19.5% (vs GSe 19.1%). The miss was primarily driven by the slow down in dental implant segment revenue (-4.4 ...

Core Points - MEDIROM Healthcare Technologies Inc. is participating in the "World" project, aimed at creating a digital infrastructure for "proof of humanness" in the AI era [2][3] - The company plans to install the World ID authentication device, "Orb," in approximately 100 Re.Ra.Ku relaxation salons, targeting access for up to 500,000 individuals [3][4] - Customers verifying their World ID can claim around 8,000 Japanese yen in Worldcoin tokens (WLD), which can be used to purchase gift certificates for Re.Ra.Ku salons [4] - Upon launching the program, the company intends to acquire WLD when customers purchase Re.Ra.Ku Tickets, with plans to exchange up to 50% of acquired WLD for Ethereum (ETH) [5] - The company aims to integrate next-generation digital infrastructure to create new value and achieve sustainable growth beyond traditional healthcare [6] Company Overview - MEDIROM operates over 300 relaxation salons in Japan under the "Re.Ra.Ku" brand, along with five other brands offering various health and wellness services [9] - The company provides health guidance and physical improvement programs through its healthcare app "Lav" and has expanded into device business with the "MOTHER Bracelet" [11] - Established in July 2000, MEDIROM is headquartered in Minato-ku, Tokyo, and is listed on NASDAQ under the ticker MRM [12]

Core Insights - UnitedHealth Group Incorporated (UNH) is expanding its network of ambulatory surgery centers (ASCs) through its Optum segment, indicating a shift in surgical practices beyond traditional hospital settings [1][4] - The expansion of ASCs allows for same-day surgical procedures across various specialties, enhancing efficiency and aligning with patient preferences for cost-effective care [2][3] - This strategic move is expected to reduce claims expenses for UNH while providing patients with lower bills and quicker recovery times, thus supporting a value-based care model [3][4] Company Performance - UNH anticipates serving 5 million patients under its fully accountable value-based care model by 2025, with Optum revenues growing by 5.8% year-over-year in the first half of 2025 [4][9] - The company's stock has seen a decline of 40% year-to-date, compared to a 31.7% decline in the industry [8] - UNH's forward price-to-earnings ratio stands at 17.42, above the industry average of 14.77, with a Zacks Value Score of B [11] Earnings Estimates - The Zacks Consensus Estimate for UNH's 2025 earnings is $16.21 per share, reflecting a 41.4% decrease from the previous year [12] - Current quarter and next quarter estimates are $2.87 and $2.02 respectively, with year-over-year growth estimates showing significant declines [13]